Rucaparib was active in patients with germline BRCA2, germline PALB2, and somatic BRCA2 variants.
Non-White and non-Hispanic patients were underrepresented throughout the period studied.
Stereotactic body radiotherapy plus pembrolizumab and trametinib improved overall and progression-free survival.
The rCOJEC regimen was less toxic than the MSKCC-N5 regimen.
A sequential treatment strategy was less effective than a maintenance strategy.